Quan Fang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7363319/publications.pdf

Version: 2024-02-01

54	1,114	393982	454577
papers	citations	19 h-index	30 g-index

55	55	55	1124
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Transient Receptor Potential Vanilloid 4 Ion Channel Functions as a Pruriceptor in Epidermal Keratinocytes to Evoke Histaminergic Itch. Journal of Biological Chemistry, 2016, 291, 10252-10262.	1.6	107
2	Astaxanthin Attenuates Early Acute Kidney Injury Following Severe Burns in Rats by Ameliorating Oxidative Stress and Mitochondrial-Related Apoptosis. Marine Drugs, 2015, 13, 2105-2123.	2.2	75
3	TRPV4 is necessary for trigeminal irritant pain and functions as a cellular formalin receptor. Pain, 2014, 155, 2662-2672.	2.0	72
4	Effects of hydrogen-rich saline on early acute kidney injury in severely burned rats by suppressing oxidative stress induced apoptosis and inflammation. Journal of Translational Medicine, 2015, 13, 183.	1.8	53
5	Inhibition of neuropeptide FF (NPFF)-induced hypothermia and anti-morphine analgesia by RF9, a new selective NPFF receptors antagonist. Regulatory Peptides, 2008, 147, 45-51.	1.9	43
6	Antinociceptive Effects of Central Administration of the Endogenous Cannabinoid Receptor Type 1 Agonist VDPVNFKLLSH-OH [(m)VD-hemopressin(Î±)], an N-Terminally Extended Hemopressin Peptide. Journal of Pharmacology and Experimental Therapeutics, 2014, 348, 316-323.	1.3	37
7	BNâ€9, a chimeric peptide with mixed opioid and neuropeptide FF receptor agonistic properties, produces nontoleranceâ€forming antinociception in mice. British Journal of Pharmacology, 2016, 173, 1864-1880.	2.7	36
8	Beneficial Effects of Hydrogen-Rich Saline on Early Burn-Wound Progression in Rats. PLoS ONE, 2015, 10, e0124897.	1.1	34
9	In vivo inhibition of neuropeptide FF agonism by BIBP3226, an NPY Y1 receptor antagonist. Peptides, 2006, 27, 2207-2213.	1.2	33
10	Preemptive intrathecal administration of endomorphins relieves inflammatory pain in male mice via inhibition of p38 MAPK signaling and regulation of inflammatory cytokines. Journal of Neuroinflammation, 2018, 15, 320.	3.1	31
11	Structure-Based Optimization of Multifunctional Agonists for Opioid and Neuropeptide FF Receptors with Potent Nontolerance Forming Analgesic Activities. Journal of Medicinal Chemistry, 2016, 59, 10198-10208.	2.9	28
12	Effects of neuropeptide FF system on CB1 and CB2 receptors mediated antinociception in mice. Neuropharmacology, 2012, 62, 855-864.	2.0	27
13	Neuropeptide FF receptors exert contractile activity via inhibition of nitric oxide release in the mouse distal colon. Peptides, 2005, 26, 791-797.	1.2	26
14	The multifunctional peptide DNâ€9 produced peripherally acting antinociception in inflammatory and neuropathic pain via Î¼â€•and Îºâ€opioid receptors. British Journal of Pharmacology, 2020, 177, 93-109.	2.7	26
15	Central Administration of Neuropeptide FF and Related Peptides Attenuate Systemic Morphine Analgesia in Mice. Protein and Peptide Letters, 2011, 18, 403-409.	0.4	25
16	<scp>G</scp>p<scp>T</scp>xâ€1 and [<scp>A</scp>la⁵, <scp>P</scp>he⁶, <scp>L</scp>eu²⁶, <scp>A</scp>rg²⁸]<scp>G</scp>p<scp>T</scp>xâ€1, two peptide <scp>N</scp>a_V1.7 inhibitors: analgesic and tolerance properties at the spinal level. British Journal of Pharmacology, 2018, 175, 3911-3927.	2.7	25
17	Neuropeptide FF receptors antagonist, RF9, attenuates opioid-evoked hypothermia in mice. Peptides, 2008, 29, 1183-1190.	1.2	23
18	The anti-inflammatory potential of neuropeptide FF in vitro and in vivo. Peptides, 2013, 47, 124-132.	1.2	22

#	Article	IF	Citations
19	Pharmacological characterization of EN-9, a novel chimeric peptide of endomorphin-2 and neuropeptide FF that produces potent antinociceptive activity and limited tolerance. Neuropharmacology, 2016, 108, 364-372.	2.0	22
20	Pressor and tachycardic responses to intrathecal administration of neuropeptide FF in anesthetized rats. Peptides, 2010, 31, 683-688.	1.2	19
21	Effects of nociceptin (13â€“17) in pain modulation at supraspinal level in mice. Neuroscience Letters, 2002, 331, 95-98.	1.0	17
22	Neuropeptide FF activates ERK and NF kappa B signal pathways in differentiated SH-SY5Y cells. Peptides, 2012, 38, 110-117.	1.2	17
23	Analgesic tolerance and cross-tolerance to the cannabinoid receptors ligands hemopressin, VD-hemopressin(Î±) and WIN55,212-2 at the supraspinal level in mice. Neuroscience Letters, 2014, 578, 187-191.	1.0	16
24	In vitro and in vivo studies of dansylated compounds, the putative agonists and antagonists on neuropeptide FF receptors. Peptides, 2006, 27, 1297-1304.	1.2	15
25	Pharmacological characterization of rat VD-hemopressin(Î±), an Î±-hemoglobin-derived peptide exhibiting cannabinoid agonist-like effects in mice. Neuropeptides, 2017, 63, 83-90.	0.9	15
26	Synthesis and Biological Characterization of Cyclic Disulfide-Containing Peptide Analogs of the Multifunctional Opioid/Neuropeptide FF Receptor Agonists That Produce Long-Lasting and Nontolerant Antinociception. Journal of Medicinal Chemistry, 2020, 63, 15709-15725.	2.9	15
27	Pharmacological effects of the dansylated neuropeptide FF analogues on body temperature and morphine analgesia. Neuropeptides, 2007, 41, 339-347.	0.9	14
28	Cardiovascular effects of intravenous administered 26RFa, a novel RFamide peptide ligand for GPR103, in anaesthetised rats. European Journal of Pharmacology, 2009, 621, 61-66.	1.7	14
29	Spinal DN-9, a Peptidic Multifunctional Opioid/Neuropeptide FF Agonist Produced Potent Nontolerance Forming Analgesia With Limited Side Effects. Journal of Pain, 2020, 21, 477-493.	0.7	14
30	Neuropeptide FF receptor antagonist, RF9, attenuates the fever induced by central injection of LPS in mice. Peptides, 2011, 32, 702-706.	1.2	13
31	The hypotensive effect of intrathecally injected (m)VD-hemopressin(Î±) in urethane-anesthetized rats. Peptides, 2014, 56, 45-51.	1.2	13
32	CB 1 cannabinoid receptor agonist mouse VD-hemopressin(Î±) produced supraspinal analgesic activity in the preclinical models of pain. Brain Research, 2018, 1680, 155-164.	1.1	12
33	Study in vitro and in vivo of nociceptin/orphanin FQ(1â€“13)NH2 analogues substituting N-Me-Gly for Gly2 or Gly3. Peptides, 2004, 25, 1349-1354.	1.2	11
34	Neuropeptide VF Enhances Cannabinoid Agonist WIN55,212-2-Induced Antinociception in Mice. Anesthesia and Analgesia, 2015, 121, 1360-1368.	1.1	11
35	Activation of NPFF2 receptor stimulates neurite outgrowth in Neuro 2A cells through activation of ERK signaling pathway. Peptides, 2016, 86, 24-32.	1.2	11
36	Development of Multifunctional and Orally Active Cyclic Peptide Agonists of Opioid/Neuropeptide FF Receptors that Produce Potent, Long-Lasting, and Peripherally Restricted Antinociception with Diminished Side Effects. Journal of Medicinal Chemistry, 2021, 64, 13394-13409.	2.9	11

#	Article	IF	Citations
37	Neuropeptide FF and related peptides attenuates warm-, but not cold-water swim stress-induced analgesia in mice. Behavioural Brain Research, 2012, 233, 428-433.	1.2	10
38	Neuropeptide FF attenuates the acquisition and the expression of conditioned place aversion to endomorphin-2 in mice. Behavioural Brain Research, 2013, 248, 51-56.	1.2	10
39	Peripheral and central sites of action for anti-allodynic activity induced by the bifunctional opioid/NPFF receptors agonist BN-9 in inflammatory pain model. European Journal of Pharmacology, 2017, 813, 122-129.	1.7	10
40	Opposite Effects of Neuropeptide FF on Central Antinociception Induced by Endomorphin-1 and Endomorphin-2 in Mice. PLoS ONE, 2014, 9, e103773.	1.1	10
41	Involvement of Sensory Neurone-TRPV4 in Acute and Chronic Itch Behaviours. Acta Dermato-Venereologica, 2022, 102, adv00651.	0.6	10
42	Systemic administration of the bifunctional opioid/neuropeptide FF receptors agonist BN-9 produced peripheral antinociception in preclinical mouse models of pain. European Journal of Pharmacology, 2018, 837, 53-63.	1.7	9
43	NPFF2 Receptor is Involved in the Modulatory Effects of Neuropeptide FF for Macrophage Cell Line. Protein and Peptide Letters, 2014, 21, 490-502.	0.4	9
44	Effects of neuropeptide FF and related peptides on the antinociceptive activities of VD-hemopressin(Îł) in naive and cannabinoid-tolerant mice. European Journal of Pharmacology, 2015, 767, 119-125.	1.7	8
45	Analgesic activities of the mixed opioid and NPFF receptors agonist DN-9 in a mouse model of formalin-induced orofacial inflammatory pain. Peptides, 2018, 110, 30-39.	1.2	8
46	Spinal microglia-derived TNF promotes the astrocytic JNK/CXCL1 pathway activation in a mouse model of burn pain. Brain, Behavior, and Immunity, 2022, 102, 23-39.	2.0	8
47	Central and peripheral modulation of gastrointestinal transit in mice by DNâ€9, a multifunctional opioid/NPFF receptor agonist. Neurogastroenterology and Motility, 2020, 32, e13848.	1.6	7
48	Spinal endomorphins attenuate burn-injury pain in male mice by inhibiting p38 MAPK signaling pathway through the mu-opioid receptor. European Journal of Pharmacology, 2021, 903, 174139.	1.7	7
49	Discovery of two novel branched peptidomimetics containing endomorphin-2 and RF9 pharmacophores: Synthesis and neuropharmacological evaluation. Bioorganic and Medicinal Chemistry, 2019, 27, 630-643.	1.4	6
50	Antinociceptive effects of the endogenous cannabinoid peptide agonist VD-hemopressin(Î²) in mice. Brain Research Bulletin, 2018, 139, 48-55.	1.4	5
51	Spinal administration of the multi-functional opioid/neuropeptide FF agonist BN-9 produced potent antinociception without development of tolerance and opioid-induced hyperalgesia. European Journal of Pharmacology, 2020, 880, 173169.	1.7	5
52	VF-13, a chimeric peptide of VD-hemopressin(Îł) and neuropeptide VF, produces potent antinociception with reduced cannabinoid-related side effects. Neuropharmacology, 2020, 175, 108178.	2.0	4
53	NOP01, a NOP receptor agonist, produced potent and peripherally restricted antinociception in a formalin-induced mouse orofacial pain model. Neuropeptides, 2022, 91, 102212.	0.9	3
54	Development and validation of a reversed phase liquid chromatographic method with fluorescence detection for the pharmacokinetic study of a new chimeric peptide. Analytical Methods, 2016, 8, 2620-2627.	1.3	1